On June 17, 2025, during the General Meeting of Shareholders, Medicalgorithmics S.A. appointed a new Supervisory Board, which in turn nominated a new Management Board. The newly elected Supervisory Board for the 2025–2028 term comprises: Attorney Michał Żółtowski (Chairman), Paweł Lewicki, Maksymilian Fraszka, Michał Wnorowski (Vice Chairman), and Marzena Piszczek.
Dr. Kris Siemionow, M.D., Ph.D. – a globally recognized expert in the medtech sector and co-founder of Biofund Capital Management LLC – who had previously served as a member of the Supervisory Board, has been appointed President of the Management Board (Chief Executive Officer). Michał Zapora, associated with the Medicalgorithmics Group since 2018 and formerly serving as Financial Controller, has been appointed Chief Financial Officer (CFO) and Member of the Management Board responsible for financial affairs.
Przemysław Tadla will continue in his capacity as Chief Technology Officer (CTO), and Jarosław Jerzakowski will remain Chief Operating Officer (COO). Given the unprecedented number of newly signed agreements and the increasing global demand for Medicalgorithmics’ proprietary technologies, Mr. Tadla and Mr. Jerzakowski will shift their focus to operational activities outside the Management Board, placing greater emphasis on the advancement of software development as well as the strengthening of global sales and distribution networks.
The year 2025 represents a pivotal period for the Polish medtech company, with Medicalgorithmics experiencing a substantial increase in interest in its solutions and an acceleration in client acquisition. Since the beginning of the year, the Company has executed 12 new commercial agreements with partners across the United States, Canada, Australia, South Korea, Turkey, and various European markets. For comparison, a total of 13 agreements were concluded throughout the entirety of 2024. Concurrently, the Company has reported a significant rise in the volume of ECG examinations, which reached 92,000 in the first quarter of 2025 – nearly a 100% year-over-year increase.
These changes in the Company’s Management Board are intended to further enhance the operational efficiency of the organization and capitalize on the current momentum. The appointment of Dr. Siemionow as CEO is expected to accelerate the Company’s global expansion, while maintaining a clear strategic focus on achieving cash flow break-even.
“It is with great pride and appreciation that I assume the role of CEO at Medicalgorithmics, a company whose growth I have supported for many years. Thanks to the dedication of our team, the excellence of our product portfolio, and the globally validated performance of our advanced DRAI artificial intelligence algorithms – as demonstrated in the prestigious DRAI Martini study published in Nature – we are entering a highly promising phase in the Company’s development. We possess the know-how, resources, and capabilities necessary to sustain dynamic growth and achieve the strategic objectives outlined in the Biofund development plan. I would like to express my gratitude to all those involved in the advancement of Medicalgorithmics. I am confident that we can look to the future with optimism and continue to set new global standards in cardiac diagnostics,” said Dr. Kris Siemionow, President of the Management Board, Medicalgorithmics S.A.
Dr. Siemionow (MD, PhD ) is an orthopedic surgeon by training and an entrepreneur who has founded and cofounded a number of medical companies that use advanced technology to improve clinical outcomes.
Dr. Siemionow completed a residency in orthopedic surgery at the Cleveland Clinic Foundation and a fellowship in spine surgery at Rush University Medical Center. His PhD focused on the effects of inflammation on nerve cell function. Dr. Siemionov is co-founder of Global Spine Outreach, a non-profit organization whose mission is “to save children with severe spinal deformities.” He is co-founder of Holo Surgical Inc, a digital surgery company that has developed an artificial intelligence-based surgical guidance system that now has clinical applications. He is also co-founder of Inteneural Networks Inc, a company that uses machine learning to diagnose neurodegenerative disorders. He is also a co-founder of Kardiolytics Inc, a company that uses artificial intelligence machine learning to develop algorithms for automated analysis of cardiovascular CT images. Dr. Siemionov has authored more than 100 peer-reviewed articles, abstracts and chapters in books on surgery and basic scientific research. He holds 50 patents and patent applications that have been successfully commercialized. Dr. Siemionov is currently a board member of Dystrogen Therapeutics, Kardiobot, Dystrogen Gene Therapeutics and Biometrics.
Michał Zapora is an experienced financial leader with over 15 years of expertise in controlling, financial reporting, and audit. He began his career in consulting firms, including a six-year tenure at EY, where he gained extensive experience in audit and business advisory. During this time, he participated in a variety of projects related to process optimization, controlling, management reporting, and risk management.
Mr. Zapora has been with Medicalgorithmics since 2018, gradually expanding his responsibilities – from Financial Analyst, to Financial Controller, and most recently Finance Manager. He is responsible for internal and external financial reporting, as well as overseeing financial processes and budgeting. Throughout his career, he has also held financial roles in technology startups, where his responsibilities included the development of financial models, financial analyses, and the implementation of reporting tools.